Navigation Links
Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America

New hire brings over 20 years of commercial life sciences sales experience to Cyntellect

SAN DIEGO, Nov. 21 /PRNewswire/ -- Cyntellect, a privately-held life sciences company leading the development and commercialization of live cell analysis and manipulation systems, announced today that it has appointed Andre Lubarsky as the Company's Director of Sales - North America. Andre will be responsible for the sales of Cyntellect's cell purification and cell health products in the life sciences research market. He joins Cyntellect with an extensive sales and sales management background at leading life sciences companies including BD Biosciences, Applied Imaging and Leica Inc.

"Andre's extensive sales and sales management experience in the life sciences research market, particularly in the cellular bioassay and analysis markets, will accelerate the commercialization of Cyntellect's products for applications in biopharmaceutical cell line development, cell line development for drug discovery and research including key applications utilizing stem cells and primary cells," said Fred Koller, Ph.D., Cyntellect's President and Chief Executive Officer. "We are very pleased to have someone of Andre's experience and customer-focused nature join the Cyntellect commercial team."

Andre comes to Cyntellect from BD Biosciences Bioimaging Systems where he filled the role of Director of Sales - North America. Prior to that, he was National Imaging Sales Manager at McBain Instruments in Chatsworth, CA. Andre joined McBain Instruments from a role as Senior Sales Manager at Applied Imaging in Santa Clara, CA. Andre's prior experience included other executive sales management positions with Leica Inc., Bio-Rad Laboratories and Cambridge Instruments. Andre graduated in Biological Sciences from the University of California - San Diego.

About Cyntellect

Cyntellect, Inc. is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The Company combines expertise in high-speed cell imaging and laser-based manipulation to develop products that enable novel cell imaging, purification, and transfection capabilities to enhance the productivity of laboratory research, recombinant protein production, high-content cellular assays, functional genomics and proteomics, and cell purification, including processing of cells for therapeutic transplantation. For additional information please visit the Company's web site at

SOURCE Cyntellect, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
2. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
3. Cyntellect to Collaborate With the Burnham Institute for Medical Research
4. InCode BioPharmaceutics Appoints New President and CEO
5. Sangamo BioSciences Appoints Paul Cleveland to Its Board of Directors and Chair of Audit Committee
6. GeneNews appoints Canadian Colorectal Cancer Advisory Board
7. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
8. TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
9. Accumetrics Appoints John J. Young, MD Chief Medical Officer
10. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
11. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
Post Your Comments:
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper ... unless it is bound to proteins, copper is also toxic to cells. With ... Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in the ...
Breaking Biology Technology:
(Date:10/26/2015)... and LAS VEGAS , Oct. 26, ... , an innovator in modern authentication and a founding ... the launch of its latest version of the Nok ... organizations to use standards-based authentication that supports existing and ... Authentication Suite is ideal for organizations deploying customer-facing applications ...
(Date:10/23/2015)... DUBLIN , Oct. 23, 2015 Research ... of the "Global Voice Recognition Biometrics Market 2015-2019" ... --> --> The global voice recognition ... during 2014-2019. --> ... 2015-2019, has been prepared based on an in-depth market ...
(Date:10/22/2015)...  Aware, Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter ended September 30, 2015.  --> ... $4.0 million, a decrease of 33% compared to $6.0 million in ... of 2015 was $2.2 million, or $0.10 per diluted share, which ... same period a year ago.  --> ...
Breaking Biology News(10 mins):